AXS-07, targeting chronic migraine, has shown promising results in Phase 3 trials but faced a CRL from the FDA due to CMC issues. The FDA has set a new PDUFA date for AXS-07 on January 31, 2025, ...
In retail channels the price difference between Rival AXS and Apex AXS is so incredibly small it makes sense to choose the upgradability of the Rival groupset. For most people though, the decision ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback